Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravesical Administration of Durvalumab (MEDI4736) to Patients With High-risk, Non-muscle-invasive Bladder Cancer (NMIBC). A Phase II Study With Correlative

Next Previous
Trial Profile

Intravesical Administration of Durvalumab (MEDI4736) to Patients With High-risk, Non-muscle-invasive Bladder Cancer (NMIBC). A Phase II Study With Correlative

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Mar 2025 Results discussing significance Intravesical Administration of Durvalumab for High-risk Non muscle-invasive Bladder Cancer, published in the European Urology
  • 04 Mar 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified March 2022).
  • 22 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top